Literature DB >> 23402032

Targeting complement at the time of transplantation.

Steven Sacks1, Julia Karegli, Conrad A Farrar, Elham Asgari, Wilhelm Schwaeble, Wuding Zhou, Richard A Smith.   

Abstract

Complement activation occurs in at least two phases when an organ is transplanted into a naive recipient: during reperfusion with recipient blood particularly when the donor organ has undergone a significant period of ischaemia and then during acute rejection once the recipient immune system has recognised the donor tissue as non-self. Both of these reactions are most obvious in the extravascular compartment of the transplanted organ and involve local synthesis of some of the key complement components as well as loss of controls that limit the activation of the pivotal component C3. In contrast, sensitised individuals with pre-existing circulating antibodies have an immediate reaction against the transplant organ that is also complement dependent but is enacted in the intravascular space. All three types of injury (ischaemia-reperfusion, acute rejection, hyperacute rejection) have a critical effect on transplant outcome. Here we discuss therapeutic strategies that are designed to overcome the impact of these factors at the start of transplantation with the aim of improving long-term transplant outcomes. These include the concept of treating the donor organ with modified therapeutic regulators that are engineered to be retained by the donor organ after transplantation and prevent inflammatory injury during the critical early period. By targeting the donor organ with anchored therapeutic proteins, the systemic functions of complement including host defence remain intact. The control of complement activation during the first stages of transplantation, including the possibility that this will reduce the capacity of the graft for stimulating the adaptive immune system, offers an important prospect for increasing the longevity of the transplant and offsetting demand on the limited supply of donor organs. It also provides a model in which the benefits and indications for localised therapy to maximise therapeutic efficiency and minimise the systemic disturbance may be instructive in other complement-related disorders.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23402032     DOI: 10.1007/978-1-4614-4118-2_17

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  12 in total

1.  New insight into the effects of heparinoids on complement inhibition by C1-inhibitor.

Authors:  F Poppelaars; J Damman; E L de Vrij; J G M Burgerhof; J Saye; M R Daha; H G Leuvenink; M E Uknis; M A J Seelen
Journal:  Clin Exp Immunol       Date:  2016-04-13       Impact factor: 4.330

Review 2.  Complement component C3 - The "Swiss Army Knife" of innate immunity and host defense.

Authors:  Daniel Ricklin; Edimara S Reis; Dimitrios C Mastellos; Piet Gros; John D Lambris
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

Review 3.  Therapeutic control of complement activation at the level of the central component C3.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Immunobiology       Date:  2015-06-10       Impact factor: 3.144

Review 4.  Complement involvement in kidney diseases: From physiopathology to therapeutical targeting.

Authors:  Maurizio Salvadori; Giuseppina Rosso; Elisabetta Bertoni
Journal:  World J Nephrol       Date:  2015-05-06

Review 5.  Update on ischemia-reperfusion injury in kidney transplantation: Pathogenesis and treatment.

Authors:  Maurizio Salvadori; Giuseppina Rosso; Elisabetta Bertoni
Journal:  World J Transplant       Date:  2015-06-24

Review 6.  Complement in immune and inflammatory disorders: therapeutic interventions.

Authors:  Daniel Ricklin; John D Lambris
Journal:  J Immunol       Date:  2013-04-15       Impact factor: 5.422

Review 7.  Complement in disease: a defence system turning offensive.

Authors:  Daniel Ricklin; Edimara S Reis; John D Lambris
Journal:  Nat Rev Nephrol       Date:  2016-05-23       Impact factor: 28.314

8.  Aberrant activation of the complement system in renal grafts is mediated by cold storage.

Authors:  Sorena Lo; Li Jiang; Savannah Stacks; Haixia Lin; Nirmala Parajuli
Journal:  Am J Physiol Renal Physiol       Date:  2021-05-17

9.  PARP inhibition attenuates acute kidney allograft rejection by suppressing cell death pathways and activating PI-3K-Akt cascade.

Authors:  Karoly Kalmar-Nagy; Peter Degrell; Aliz Szabo; Katalin Sumegi; Istvan Wittmann; Ferenc Gallyas; Balazs Sumegi
Journal:  PLoS One       Date:  2013-12-03       Impact factor: 3.240

Review 10.  The complement cascade and renal disease.

Authors:  Katarzyna Kościelska-Kasprzak; Dorota Bartoszek; Marta Myszka; Marcelina Zabińska; Marian Klinger
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2013-09-13       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.